Source:http://linkedlifedata.com/resource/umls/id/C0039600
MSH: An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.,PDQ: A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42916&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42916&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2301" NCI Thesaurus),NCI: A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. (NCI04)